Home
Issues
Aim & Scope
Open Access
Editorial Board
Indexing
Why publish with us
Contact us
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Data Policies
Publication Ethics and Publication Malpractice Statement
ORIGINAL STUDY
A biobank for Interstitial Lung Diseases according to the European Network “eurIPF” and “ΒΒ ΜRI”
1
Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece
2
Laboratory of Pharmacology, Medical School, Democritus University of Thrace
3
University of Giessen Lung Center Justus-Liebig, Germany
4
Histology Laboratory, Democritus University of Thrace
5
Cardiothoracic Surgery Clinic, Democritus University of Thrace and University Hospital of Evros
6
Biomedical Research Center “Alexander Fleming”, Athens
Corresponding author
Demosthenes Bouros
Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece 68100 Alexandroupolis
Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece 68100 Alexandroupolis
Pneumon 2014;27(3):209-213
KEYWORDS
ABSTRACT
The creation of a Biobank for Interstitial Lung Diseases (ILDs), according to the standards set by the European Idiopathic Pulmonary Fibrosis Registry (eurIPFreg) and Biobanking and Biomolecular Research Infrastructure (BBMRI) is a major step in the understanding of these highly complex diseases. Particular emphasis is placed on Idiopathic Interstitial Pneumonias and especially Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive fibrotic interstitial pneumonia, with an average life span of 3 years. Our aim is to present a methodological guide for the development of a biobank for ILDs.
FUNDING
This project entitled “Functional genomics in the
pathogenesis of pulmonary fibrosis. Discovery of pathogenic mechanisms and new therapeutic targets”, code
09-CO-12-680, was funded by the Operational Programme
“Competitiveness and Entrepreneurship” of Regions in
Transition that operates under the National Strategic
Reference Framework, NSRF 2007-2013.
REFERENCES (14)
1.
Bouros D. Idiopathic interstitial pneumonias: Classification revision. Pneumon 2010;23:359-62.
2.
Bouros D. Guidelines for the management of respiratory diseases: From the international guidelines to the hellenic reality. Pneumon 2012;25:Suppl 1.
3.
Antoniou KM, Daniil Z, Polychronopoulos V, Papiris S, Bouros D. Pneumon 2012;25(Suppl 1):110-2.
4.
Travis WD, Costabel U, Hansell DM, et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
5.
Bouros D. Current therapy of idiopathic pulmonary fibrosis: Primum non noccere! Pneumon 2012;25:259-61.
6.
Bouros D. Idiopathic pulmonary fibrosis: The dawn of a new era. Pneumon 2014;27:117-9.
7.
Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014;2:17-9.
8.
Guenther A; European IPF Network. The European IPF Network: towards better care for a dreadful disease. Eur Respir J 2011;37:747-8.
9.
Yuille M, van Ommen GJ, Bréchot C, et al. Biobanking for Europe. Brief Bioinform 2008;9:14-24.
10.
Holub P, Greplova K, Knoflickova D, Nenutil R, Valik D. The biobanking research infrastructure BBMRI_CZ: a critical tool to enhance translational cancer research. Klin Onkol 2012;25 (Suppl 2):2S78-81.
11.
Kubáň P, Foret F. Exhaled breath condensate: determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review. Anal Chim Acta 2013;805:1-18.
12.
Calzolari A, Valerio A, Capone F, et al. The European Research Infrastructures of the ESFRI Roadmap in Biological and Medical Sciences: status and perspectives. Ann Ist Super Sanita 2014;50:178-85.
13.
Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. Brief Funct Genomic Proteomic 2007;6:193-201.
14.
Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
